Supplemental Tables 1 and 2

These tables summarize the reported literature on the use of systemic Rituximab in patients with primary cutaneous folicular center cell lymphomas (PCFCL) and primary cutaneous marginal zone lymphomas (PCMZL). The tables include information regarding type of lymphoma, doses, response and outcome. These data are usuful to be compared with that of our present investigation

本表格汇总了原发性皮肤滤泡中心细胞淋巴瘤（primary cutaneous folicular center cell lymphomas, PCFCL）与原发性皮肤边缘区淋巴瘤（primary cutaneous marginal zone lymphomas, PCMZL）患者全身应用利妥昔单抗（Rituximab）的已发表研究文献。表格涵盖了淋巴瘤分型、给药剂量、治疗应答及临床结局等相关信息，可用于与本研究的数据进行对照比较。